NKTR – Nektar Therapeutics
Nektar TherapeuticsNKTR
$22.96Name : Nektar Therapeutics
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $398,521,312.00
EPSttm : -9.45
Nektar Therapeutics
$22.96
5.90%$1.28Float Short %
6.91
Margin Of Safety %
Put/Call OI Ratio
0.28
EPS Next Q Diff
-2.38
EPS Last/This Y
-1.31
EPS This/Next Y
-1.16
Price
22.96
Target Price
94.83
Analyst Recom
1.75
Performance Q
96.21
Relative Volume
0.28
Beta
0.96
Ticker: NKTR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-04 | NKTR | 24.76 | 0.51 | 0.71 | 82517 |
| 2025-07-07 | NKTR | 23.59 | 0.52 | 0.51 | 83182 |
| 2025-07-08 | NKTR | 22.73 | 0.52 | 0.93 | 83872 |
| 2025-07-09 | NKTR | 23.36 | 0.51 | 0.29 | 83766 |
| 2025-07-10 | NKTR | 25.19 | 0.50 | 0.24 | 85230 |
| 2025-07-11 | NKTR | 24.99 | 0.48 | 0.42 | 85691 |
| 2025-07-14 | NKTR | 24.48 | 0.49 | 0.18 | 86957 |
| 2025-07-15 | NKTR | 23.86 | 0.48 | 0.16 | 87511 |
| 2025-07-16 | NKTR | 24.2 | 0.48 | 0.09 | 88653 |
| 2025-07-17 | NKTR | 26.68 | 0.47 | 0.09 | 89490 |
| 2025-07-18 | NKTR | 24.94 | 0.47 | 0.19 | 92046 |
| 2025-07-21 | NKTR | 24.8 | 0.18 | 0.81 | 54918 |
| 2025-07-22 | NKTR | 24.47 | 0.20 | 0.61 | 56788 |
| 2025-07-23 | NKTR | 24.98 | 0.22 | 1.36 | 58236 |
| 2025-07-24 | NKTR | 24.26 | 0.24 | 0.53 | 59654 |
| 2025-07-25 | NKTR | 25.02 | 0.25 | 0.11 | 59984 |
| 2025-07-28 | NKTR | 23.65 | 0.25 | 1.12 | 60990 |
| 2025-07-29 | NKTR | 22.91 | 0.25 | 2.91 | 61442 |
| 2025-07-30 | NKTR | 22.14 | 0.27 | 0.90 | 62787 |
| 2025-07-31 | NKTR | 21.71 | 0.28 | 0.35 | 63905 |
| 2025-08-01 | NKTR | 22.88 | 0.28 | 0.16 | 64164 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-04 | NKTR | 24.76 | 0.7 | - | -11.19 |
| 2025-07-07 | NKTR | 23.59 | 0.7 | - | -11.19 |
| 2025-07-08 | NKTR | 22.73 | 0.7 | - | -11.19 |
| 2025-07-09 | NKTR | 23.36 | 0.7 | - | -11.19 |
| 2025-07-10 | NKTR | 25.10 | 0.7 | - | -11.19 |
| 2025-07-11 | NKTR | 25.01 | 0.7 | - | -11.19 |
| 2025-07-14 | NKTR | 24.41 | 0.7 | - | -11.19 |
| 2025-07-15 | NKTR | 23.80 | 0.7 | - | -11.19 |
| 2025-07-16 | NKTR | 24.17 | 0.7 | - | -11.19 |
| 2025-07-17 | NKTR | 26.67 | 0.7 | - | -11.19 |
| 2025-07-18 | NKTR | 24.92 | 0.7 | - | -11.19 |
| 2025-07-21 | NKTR | 24.82 | 0.7 | - | -11.19 |
| 2025-07-22 | NKTR | 24.52 | 0.7 | - | -11.19 |
| 2025-07-23 | NKTR | 25.00 | 0.7 | - | -11.19 |
| 2025-07-24 | NKTR | 24.58 | 0.7 | - | -11.19 |
| 2025-07-25 | NKTR | 25.00 | 0.7 | - | -10.01 |
| 2025-07-28 | NKTR | 23.69 | -11.1 | - | -10.01 |
| 2025-07-29 | NKTR | 22.91 | -11.1 | - | -10.01 |
| 2025-07-30 | NKTR | 22.07 | -11.1 | - | -10.01 |
| 2025-07-31 | NKTR | 21.68 | -11.1 | - | -10.01 |
| 2025-08-01 | NKTR | 22.96 | -11.1 | - | -10.01 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-04 | NKTR | -16.66 | 0 | 4.98 |
| 2025-07-07 | NKTR | -12.96 | 0 | 0 |
| 2025-07-08 | NKTR | -12.96 | 0 | 3.71 |
| 2025-07-09 | NKTR | -12.54 | 0 | 0 |
| 2025-07-10 | NKTR | -12.54 | 0 | 3.57 |
| 2025-07-11 | NKTR | -1.90 | 0 | 9.57 |
| 2025-07-14 | NKTR | -1.90 | 5.15 | 9.45 |
| 2025-07-15 | NKTR | -1.98 | 5.15 | 9.45 |
| 2025-07-16 | NKTR | -1.98 | 5.15 | 9.45 |
| 2025-07-17 | NKTR | -1.98 | 5.15 | 9.45 |
| 2025-07-18 | NKTR | -1.98 | 5.15 | 9.45 |
| 2025-07-21 | NKTR | -1.98 | 27.61 | 7.22 |
| 2025-07-22 | NKTR | -16.79 | 27.61 | 7.22 |
| 2025-07-23 | NKTR | -16.79 | 27.61 | 7.22 |
| 2025-07-24 | NKTR | -16.79 | 27.61 | 7.22 |
| 2025-07-25 | NKTR | -16.79 | 27.61 | 6.91 |
| 2025-07-28 | NKTR | -16.79 | 36.29 | 6.91 |
| 2025-07-29 | NKTR | -16.79 | 36.29 | 6.91 |
| 2025-07-30 | NKTR | -16.79 | 36.29 | 6.91 |
| 2025-07-31 | NKTR | -16.79 | 36.29 | 6.91 |
| 2025-08-01 | NKTR | -16.79 | 36.29 | 6.91 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.24
Avg. EPS Est. Current Quarter
-2.79
Avg. EPS Est. Next Quarter
-2.62
Insider Transactions
-16.79
Institutional Transactions
36.29
Beta
0.96
Average Sales Estimate Current Quarter
9
Average Sales Estimate Next Quarter
9
Fair Value
Quality Score
29
Growth Score
28
Sentiment Score
45
Actual DrawDown %
94.3
Max Drawdown 5-Year %
-98.3
Target Price
94.83
P/E
Forward P/E
PEG
P/S
4.55
P/B
20.74
P/Free Cash Flow
EPS
-9.53
Average EPS Est. Cur. Y
-10.01
EPS Next Y. (Est.)
-11.18
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-152.49
Relative Volume
0.28
Return on Equity vs Sector %
-992.2
Return on Equity vs Industry %
-973.5
EPS 1 7Days Diff
1.2
EPS 1 30Days Diff
1.17
EBIT Estimation
Nektar TherapeuticsSector: Healthcare
Industry: Biotechnology
Employees: 61
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
stock quote shares NKTR – Nektar Therapeutics Stock Price stock today
news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025
marketwatch NKTR – Nektar Therapeutics yahoo finance google finance
stock history NKTR – Nektar Therapeutics invest stock market
stock prices NKTR premarket after hours
ticker NKTR fair value insiders trading